Stockreport

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]

Vigil Neuroscience, Inc.  (VIGL) 
PDF – E nrollment for IGNITE trial completed with 20 patients enrolled; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer clinical trial evaluating VG-3 [Read more]